U.S. Diabetic Neuropathy Market Report 2022: Adoption of Inorganic Growth Strategies Fuels Sector – ResearchAndMarkets.com

U.S. Diabetic Neuropathy Market Report 2022: Adoption of Inorganic Growth Strategies Fuels Sector – ResearchAndMarkets.com




U.S. Diabetic Neuropathy Market Report 2022: Adoption of Inorganic Growth Strategies Fuels Sector – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “U.S. Diabetic Neuropathy Market, by Drug by Type, by Route of Administration, by Distribution Channel – Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030” report has been added to ResearchAndMarkets.com’s offering.

Diabetic neuropathy is a serious and common complication of type 1 and type 2 diabetes. Diabetic neuropathy is the damage caused to the nerve due to diabetes which often leads to pain and numbness in feet or lower leg, it develops slowly, sometimes over the course of decades. The pain can be experienced in other parts of the body such as hips, wrist and back depending upon the effect of neuropathy.

There are different types of neuropathy such as focal neuropathy, proximal neuropathy, peripheral neuropathy and autonomic neuropathy. Peripheral neuropathy is the most common form of neuropathy.

Over time, high blood glucose levels, also called blood sugar, and high levels of fats, such as triglycerides, in the blood from diabetes can damage your nerves. High blood glucose levels can also damage the small blood vessels that nourishes the nerves with oxygen and nutrients. There is no cure for diabetic neuropathy but the nerve pain can be managed with medication and exercise.

Market Dynamics

Increasing adoption of inorganic strategies such as collaborative agreement by key market players is expected to drive the U.S. diabetic neuropathy market over the forecast period.

For instance, in June 2020, NeuroMetrix, Inc., a medical device company, announced that they had signed a collaborative agreement with BioMedix, a manufacturer of diagnostic and surgical equipment, to comarket DPNCheck for peripheral neuropathy detection within medicare advantage. This agreement will provide complementary diagnostic tests to physicians and health plans by combining results from multiple diagnostic tests into one data exchange file for the electronic medical record system.

Key features of the study:

  • This report provides an in-depth analysis of the U.S. diabetic neuropathy market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the U.S. diabetic neuropathy market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Eli Lilly and Company, Johnson & Johnson Services, Inc., Novartis AG, Pfizer, Inc., GSK plc., Glenmark Pharmaceuticals Ltd., Lupin, Regenacy Pharmaceuticals, Inc., Alembic Pharmaceuticals Limited, Abbott, Ionis Pharmaceuticals, NeuroMetrix, Inc., Tissue Tech, Inc., and Averitas Pharma, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The U.S. diabetic neuropathy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. diabetic neuropathy market

Detailed Segmentation:

U.S. Diabetic Neuropathy Market, By Drug:

  • Tricyclic Antidepressants
  • Amitriptyline
  • Nortyptyline
  • Imipramine
  • Desipramine
  • SSRI
  • Paroxetine
  • Citalopram
  • Anticonvulsants
  • Gabapentin
  • Pregabalin
  • Carbamazepine
  • Others (Oxcarbazepine, Topiramate and Others)
  • Opioids
  • Tramadol
  • Tapentadol
  • Oksikodon
  • SNRIs
  • Duloxetine
  • Other Drugs
  • Capsaicin
  • Lidocaine
  • Botilinum Toxin

U.S. Diabetic Neuropathy Market, By Type:

  • Peripheral Neuropathy
  • Proximal Neuropathy
  • Autonomic Neuropathy
  • Focal Neuropathy

U.S. Diabetic Neuropathy Market, By Route of Administration:

  • Oral
  • Topical
  • Injection (Intramuscular)

U.S. Diabetic Neuropathy Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Company Profiles

  • Eli Lilly and Company
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Pfizer, Inc.
  • GSK plc.
  • Glenmark Pharmaceuticals Ltd.
  • Lupin
  • Regenacy Pharmaceuticals, Inc.
  • Alembic Pharmaceuticals Limited
  • Abbott
  • Ionis Pharmaceuticals
  • NeuroMetrix, Inc.
  • Tissue Tech, Inc.
  • Averitas Pharma, Inc.

Key Topics Covered:

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. U.S. Diabetic Neuropathy Market – Impact of Coronavirus (Covid-19) Pandemic

5. U.S. Diabetic Neuropathy Market, By Drug, 2017 – 2030, (US$ Million)

6. U.S. Diabetic Neuropathy Market, By Type, 2017 – 2030, (US$ Million)

7. U.S. Diabetic Neuropathy Market, By Route of Administration, 2017 – 2030, (US$ Million)

8. U.S. Diabetic Neuropathy Market, By Distribution Channel, 2017 – 2030, (US$ Million)

9. Competitive Landscape

10. Section

Companies Mentioned

  • Eli Lilly and Company
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Pfizer, Inc.
  • GSK plc.
  • Glenmark Pharmaceuticals Ltd.
  • Lupin
  • Regenacy Pharmaceuticals, Inc.
  • Alembic Pharmaceuticals Limited
  • Abbott
  • Ionis Pharmaceuticals
  • NeuroMetrix, Inc.
  • Tissue Tech, Inc.
  • Averitas Pharma, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/e71ggs

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900